Abaloparatide
Abaloparatide (PTHrP Analogue)
A synthetic analogue of PTHrP (parathyroid hormone-related protein) fragment 1-34. FDA-approved (Tymlos) for osteoporosis with a more anabolic and less catabolic profile than teriparatide.
Mechanism of Action
Abaloparatide selectively activates the RG conformation of PTH1R, producing a more anabolic and less catabolic bone response than teriparatide. It has a shorter receptor occupancy time, reducing bone resorption.
Health Claims & Evidence
Anabolic bone building with superior fracture reduction vs teriparatide
Reduces vertebral and non-vertebral fracture risk
More anabolic and less catabolic than teriparatide
Short-Term Effects
Bone density increases measurable within months.
Long-Term Effects
Significant bone density gains and fracture risk reduction.
Side Effects
Hypercalciuria, dizziness, nausea, palpitations.
Contraindications
Similar to teriparatide. Maximum 2-year lifetime use.
This profile is provided for educational research only. It is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Verify primary sources and consult a qualified healthcare professional for medical decisions.
Research Papers
Abaloparatide and fracture risk reduction
Miller et al. · JAMA · 2016
Educational research only. This profile is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Consult a qualified healthcare professional for medical decisions.
Related Peptides
Explore the research further
Our AI Research Advisor can help you explore the evidence on Abaloparatide and related peptides, and prepare an educational research summary.
Explore Research